WHI Premarin Announcement Is Imminent
This article was originally published in The Pink Sheet Daily
Executive Summary
NIH is expected to discuss the future direction of the estrogen-only arm of the WHI study March 2.
You may also be interested in...
Wyeth Post-WHI R&D Focusing On Non-Hormonal Therapies
Wyeth's post-WHI research and development activities are focusing on developing more targeted hormone replacement therapies, as well as non-hormonal options for post-menopausal women
Premarin WHI Results May Mean Additional Label Changes, FDA Says
The findings could lead FDA to revise the class labeling for hormone therapies to reflect the absence of risk of heart disease and invasive breast cancer among estrogen-only patients.
Wyeth Post-WHI R&D Focusing On Non-Hormonal Therapies
Wyeth's post-WHI research and development activities are focusing on developing more targeted hormone replacement therapies, as well as non-hormonal options for post-menopausal women